{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:29:42Z","timestamp":1793608182094,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.berh.2026.102164","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:23:27Z","timestamp":1780658607000},"page":"102164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pneumocystis prophylaxis in rheumatic disease"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5061-2134","authenticated-orcid":false,"given":"Rachel M.","family":"Wolfe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.berh.2026.102164_bib1","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3390\/jof7110979","article-title":"Transmission and colonization of Pneumocystis jirovecii","volume":"7","author":"Vera","year":"2021","journal-title":"J Fungi (Basel)"},{"issue":"4","key":"10.1016\/j.berh.2026.102164_bib2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrmicro1621","article-title":"Current insights into the biology and pathogenesis of pneumocystis pneumonia","volume":"5","author":"Thomas","year":"2007","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"10.1016\/j.berh.2026.102164_bib3","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3899\/jrheum.090843","article-title":"A survey of rheumatologists' practice for prescribing pneumocystis prophylaxis","volume":"37","author":"Cettomai","year":"2010","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2026.102164_bib4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/RHU.0b013e31817a7e30","article-title":"Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature","volume":"14","author":"Gupta","year":"2008","journal-title":"J Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2026.102164_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz315","article-title":"Practice patterns of pneumocystis pneumonia prophylaxis in connective tissue diseases: a survey of infectious disease physicians","volume":"6","author":"Wolfe","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.berh.2026.102164_bib6","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4065\/82.9.1052","article-title":"Prophylaxis of pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials","volume":"82","author":"Green","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.berh.2026.102164_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005590.pub3","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.berh.2026.102164_bib9","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1002\/art.42541","article-title":"Risk-benefit analysis of primary prophylaxis against Pneumocystis Jirovecii pneumonia in patients with rheumatic diseases receiving rituximab","volume":"75","author":"Park","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102164_bib10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12941-021-00483-2","article-title":"Epidemiology, mortality and effectiveness of prophylaxis for Pneumocystis jiroveci pneumonia among rheumatic patients: a territory-wide study","volume":"20","author":"Chan","year":"2021","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"3","key":"10.1016\/j.berh.2026.102164_bib11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.semarthrit.2011.05.004","article-title":"Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases","volume":"41","author":"Vananuvat","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2026.102164_bib12","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2026.102164_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/PL00021707","article-title":"Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy","volume":"15","author":"Ogawa","year":"2005","journal-title":"Mod Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2026.102164_bib14","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2026.102164_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.berh.2026.102164_bib16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.berh.2026.102164_bib17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00296-007-0505-4","article-title":"Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease","volume":"28","author":"Kimura","year":"2008","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.berh.2026.102164_bib18","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.semarthrit.2018.10.018","article-title":"Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs","volume":"48","author":"Schmajuk","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2026.102164_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4065\/71.1.5","article-title":"Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy","volume":"71","author":"Yale","year":"1996","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.berh.2026.102164_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11926-017-0664-6","article-title":"Pneumocystis pneumonia and the rheumatologist: which patients are at risk and how can PCP be prevented?","volume":"19","author":"Wolfe","year":"2017","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.berh.2026.102164_bib21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01.rhu.0000221794.24431.36","article-title":"Pneumocystis carinii pneumonia in patients with connective tissue disease","volume":"12","author":"Li","year":"2006","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2026.102164_bib22","first-page":"671","article-title":"Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience","volume":"35","author":"Mecoli","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2026.102164_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292507","article-title":"Pneumocystis jirovecii pneumonia mortality risk associated with preceding long-term steroid use for the underlying disease: a multicenter, retrospective cohort study","volume":"19","author":"Miyake","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.berh.2026.102164_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152257","article-title":"Risk factors for invasive fungal infections in patients with connective tissue disease: systematic review and meta-analysis","volume":"63","author":"Xiong","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2026.102164_bib25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/annrheumdis-2017-212588","article-title":"Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question","volume":"77","author":"Winthrop","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2026.102164_bib26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/RHU.0000000000000215","article-title":"Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid","volume":"21","author":"Chew","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.berh.2026.102164_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152154","article-title":"Is there a role for Pneumocystis jiroveci pneumonia prophylaxis in giant cell arteritis or polymyalgia rheumatica?","volume":"58","author":"Anumolu","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2026.102164_bib28","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1378\/chest.118.3.712","article-title":"Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection","volume":"118","author":"Mansharamani","year":"2000","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.berh.2026.102164_bib29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13075-021-02606-8","article-title":"High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center","volume":"23","author":"Huang","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"6\u20137","key":"10.1016\/j.berh.2026.102164_bib30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/00365540601150497","article-title":"Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004","volume":"39","author":"Overgaard","year":"2007","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"10.1016\/j.berh.2026.102164_bib31","first-page":"152","article-title":"Pneumocystis jirovecii Pneumonia prophylaxis in patients with ANCA vasculitis on rituximab maintenance therapy","volume":"4","author":"Aqeel","year":"2024","journal-title":"Glomerular Dis"},{"issue":"4","key":"10.1016\/j.berh.2026.102164_bib36","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M","article-title":"Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality","volume":"42","author":"Ward","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2026.102164_bib32","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/ard.54.12.991","article-title":"Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis","volume":"54","author":"Godeau","year":"1995","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2026.102164_bib33","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.semarthrit.2016.09.009","article-title":"Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: a case-control study","volume":"46","author":"Tadros","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2026.102164_bib34","first-page":"1186","article-title":"Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis\/dermatomyositis or systemic lupus erythematosus","volume":"23","author":"Kadoya","year":"1996","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2026.102164_bib35","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s10067-025-07392-1","article-title":"Characteristics and prognostic analysis of Pneumocystis jirovecii pneumonia in connective tissue diseases patients with interstitial lung disease: a retrospective study","volume":"44","author":"Shi","year":"2025","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2026.102164_bib37","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/ard-2023-224819","article-title":"Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry","volume":"83","author":"de Valence","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102164_bib38","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/ajrccm.151.3.7881673","article-title":"Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis","volume":"151","author":"Ognibene","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.berh.2026.102164_bib39","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","article-title":"A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis","volume":"40","author":"Guillevin","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2026.102164_bib40","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2026.102164_bib41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2026.102164_bib42","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"3S","key":"10.1016\/j.berh.2026.102164_bib43","first-page":"S71","article-title":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"19","key":"10.1016\/j.berh.2026.102164_bib44","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.berh.2026.102164_bib45","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.berh.2026.102164_bib46","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/acr.20435","article-title":"Pneumocystis jiroveci pneumonia in giant cell arteritis: a case series","volume":"63","author":"Kermani","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.berh.2026.102164_bib47","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"American college of rheumatology\/vasculitis foundation guideline for the management of giant cell arteritis and takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102164_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152106","article-title":"Rates of Pneumocystis jirovecii pneumonia and prophylaxis prescribing patterns in a large electronic health record cohort of patients with systemic lupus erythematosus","volume":"57","author":"Boone","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2026.102164_bib49","first-page":"265","article-title":"Antibiotic allergy in systemic lupus erythematosus: a case-control study","volume":"19","author":"Petri","year":"1992","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2026.102164_bib50","first-page":"480","article-title":"Frequency of adverse drug reactions in patients with systemic lupus erythematosus","volume":"30","author":"Pope","year":"2003","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2026.102164_bib51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jiac.2018.11.014","article-title":"Effectiveness and safety of lower dose sulfamethoxazole\/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: a retrospective multicenter study","volume":"25","author":"Ohmura","year":"2019","journal-title":"J Infect Chemother"},{"issue":"4","key":"10.1016\/j.berh.2026.102164_bib52","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3109\/14397595.2015.1112467","article-title":"Safety and efficacy of upfront graded administration of trimethoprim\u2013sulfamethoxazole in systemic lupus erythematosus: a retrospective cohort study","volume":"26","author":"Suyama","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2026.102164_bib53","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/art.43212","article-title":"American college of rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis","volume":"77","author":"Sammaritano","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102164_bib54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semarthrit.2010.08.003","article-title":"Infectious complications in polymyositis and dermatomyositis: a series of 279 patients","volume":"41","author":"Marie","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2026.102164_bib55","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10067-006-0441-9","article-title":"Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review","volume":"26","author":"Falagas","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2026.102164_bib56","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/rheumatology\/keaa436","article-title":"Risk factors associated with Pneumocystis jirovecii pneumonia in juvenile myositis in North America","volume":"60","author":"Sabbagh","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.berh.2026.102164_bib57","first-page":"218","article-title":"Pneumocystis jirovecii pneumonia in anti-MDA5-positive dermatomyositis: characterisation, risk factors and prognosis","volume":"44","author":"Yang","year":"2026","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2026.102164_bib58","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10067-022-06403-9","article-title":"Clinical characteristics of and risk factors for Pneumocystis jirovecii pneumonia in anti-melanoma differentiation-associated gene 5 (Anti-MDA5) antibody-positive dermatomyositis patients: a single-center retrospective study","volume":"42","author":"Li","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2026.102164_bib59","article-title":"American college of rheumatology guidance statement for diagnosis and management of VEXAS developed by the international VEXAS working group expert panel","author":"Mekinian","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2026.102164_bib60","doi-asserted-by":"crossref","first-page":"e734","DOI":"10.1016\/S2665-9913(25)00225-5","article-title":"Mapping the infectious burden in VEXAS syndrome: a systematic review and rationale for prevention","volume":"7","author":"Ribier","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2026.102164_bib61","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae405","article-title":"Opportunistic infections, mortality risk, and prevention strategies in patients with vacuoles, E1 enzyme, X-Linked, autoinflammatory, somatic (VEXAS) syndrome","volume":"11","author":"Czech","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.berh.2026.102164_bib62","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1756-185X.2012.01728.x","article-title":"Incidence rate and causes of infection in Thai systemic sclerosis patients","volume":"15","author":"Foocharoen","year":"2012","journal-title":"Int J Rheum Dis"},{"issue":"25","key":"10.1016\/j.berh.2026.102164_bib63","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.berh.2026.102164_bib64","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.berh.2026.102164_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.70126","article-title":"Combining pirfenidone with mycophenolate mofetil for systemic sclerosis-related interstitial lung disease (scleroderma lung study III): an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled phase 2 trial","volume":"7","author":"Khanna","year":"2025","journal-title":"ACR Open Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2026.102164_bib66","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/cid\/ciu185","article-title":"Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis","volume":"58","author":"Kourbeti","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.berh.2026.102164_bib67","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1136\/annrheumdis-2013-203407","article-title":"Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety assessment of biologic ThERapy (SABER) study","volume":"73","author":"Baddley","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2026.102164_bib68","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11926-014-0445-4","article-title":"Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis","volume":"16","author":"Grubbs","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.berh.2026.102164_bib69","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1093\/rheumatology\/keaf052","article-title":"Incidence of ANCA-associated vasculitis and polyarteritis nodosa in Norfolk, UK, from 2011 to 2020","volume":"64","author":"Fordham","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.berh.2026.102164_bib70","article-title":"Pneumocystis jirovecii pneumonia in rheumatology patients - a single centre ten-year audit","volume":"64","author":"Fernandez","year":"2025","journal-title":"Rheumatology"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:11:35Z","timestamp":1793607095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1521694226000495"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102164","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumocystis prophylaxis in rheumatic disease","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102164"}}